{"id":64,"date":"2023-01-02T05:13:07","date_gmt":"2023-01-02T05:13:07","guid":{"rendered":"https:\/\/kurir-health.com\/?p=64"},"modified":"2023-05-25T11:47:01","modified_gmt":"2023-05-25T11:47:01","slug":"u-s-fda-clears-ind-for-first-in-class-anti-b7h7-antibody-announces-harbour-biomed","status":"publish","type":"post","link":"https:\/\/kurir-health.com\/?p=64","title":{"rendered":"U.S. FDA Clears IND for First-in-Class Anti-B7H7 Antibody, Announces Harbour BioMed"},"content":{"rendered":"\n<ul class=\"wp-block-list\">\n<li>HBM1020, the first fully human monoclonal anti-B7H7 antibody in the world class, is available now.<\/li>\n\n\n\n<li>HBM1020, the first monoclonal anti-B7H7 antibody ever cleared for clinical trials by the regulatory agency, is the world&#8217;s first.<\/li>\n\n\n\n<li>HBM1020 could be a new anti-tumor therapy that complements PD(L)1 therapies, particularly for PDL1-negative\/refractory cancer patients.<\/li>\n<\/ul>\n\n\n\n<p>Harbour BioMed, HKEX 02142 (the &#8220;Company&#8221;) announced that the U.S. Food and Drug Administration has approved the application for an investigational new drug to begin clinical trials in the U.S. of its first-in class fully human monoclonal antibodies HBM1020 against B7H7.&nbsp;This multicenter, open-label study will evaluate HBM1020&#8217;s safety, tolerability and pharmacokinetics as well as its anti-tumor effect in patients with advanced solid tumours.&nbsp;HBM1020 was also the first monoclonal B7H7 antibody to be cleared for clinical trials by the regulatory agency.<\/p>\n\n\n\n<p>HBM1020, a fully human monoclonal anti-B7H7 antibody is the first of its kind. It was generated using the Harbour Mice&nbsp;<sup>(r)<\/sup>&nbsp;H2L2 platform.&nbsp;The antibody is able to enhance anti-tumor immune response by blocking the novel target of immune checkpoint.&nbsp;Preclinical studies demonstrated that the antibody&#8217;s immune activation and antitumor functions were functional.<\/p>\n\n\n\n<p>B7H7 belongs to the B7 family of immune modulatory molecules.&nbsp;These pathways are very attractive for cancer immunotherapy because the B7 family plays a central role in regulating T-cell responses.&nbsp;The majority of immune-oncology targets that have been validated so far, such as PD-(L), and CTLA-4, are part of the B7 family.&nbsp;Therapies against B7 targets have already changed the paradigm of cancer treatment with impressive clinical benefits.&nbsp;B7H7 is a recently discovered member of B7 family. Its expression does not overlap with PDL1 in many tumor types. This indicates that there are other immune evasion pathways besides PD(L)1.&nbsp;In PDL1-negative\/refractory cancer patients, B7H7 may play a greater role in the tumor cells, allowing them to escape immune surveillance. This is expected to lead to next-generation immuno-oncology therapies.<\/p>\n\n\n\n<p>HBM1020, with its novel biology mechanisms, may offer a new anti-tumor therapy that is complementary to PD(L)1 therapies, particularly for PDL1-negative\/refractory cancer patients.<\/p>\n\n\n\n<figure class=\"wp-block-image size-full\"><img loading=\"lazy\" decoding=\"async\" width=\"768\" height=\"305\" src=\"https:\/\/kurir-health.com\/wp-content\/uploads\/2023\/05\/image-28.png\" alt=\"\" class=\"wp-image-174\" srcset=\"https:\/\/kurir-health.com\/wp-content\/uploads\/2023\/05\/image-28.png 768w, https:\/\/kurir-health.com\/wp-content\/uploads\/2023\/05\/image-28-300x119.png 300w\" sizes=\"auto, (max-width: 768px) 100vw, 768px\" \/><\/figure>\n","protected":false},"excerpt":{"rendered":"<p>Harbour BioMed, HKEX 02142 (the &#8220;Company&#8221;) announced that the U.S. Food and Drug Administration has approved the application for an investigational new drug to begin clinical trials in the U.S. of its first-in class fully human monoclonal antibodies HBM1020 against B7H7.&nbsp;This multicenter, open-label study will evaluate HBM1020&#8217;s safety, tolerability and pharmacokinetics as well as its [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":65,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[7],"tags":[],"class_list":["post-64","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-cancer"],"_links":{"self":[{"href":"https:\/\/kurir-health.com\/index.php?rest_route=\/wp\/v2\/posts\/64","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/kurir-health.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/kurir-health.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/kurir-health.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/kurir-health.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=64"}],"version-history":[{"count":2,"href":"https:\/\/kurir-health.com\/index.php?rest_route=\/wp\/v2\/posts\/64\/revisions"}],"predecessor-version":[{"id":282,"href":"https:\/\/kurir-health.com\/index.php?rest_route=\/wp\/v2\/posts\/64\/revisions\/282"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/kurir-health.com\/index.php?rest_route=\/wp\/v2\/media\/65"}],"wp:attachment":[{"href":"https:\/\/kurir-health.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=64"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/kurir-health.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=64"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/kurir-health.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=64"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}